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Protein-losing enteropathy in systemic 
lupus erythematosus: case report
Fernando Moreira Batista Aguiar1, Zilaís Linhares Carneiro Menescal1, Débora Maia da Costa2, 
José Walter Correia3, José Gerardo Araújo Paiva4, Júlio Marcus Sousa Correia5
ABSTRACT
Protein-losing enteropathy is rarely seen in patients with systemic lupus erythematosus. This clinical condition should be 
suspected in the presence of persistent hypoalbuminemia despite normal liver function, adequate protein intake, and no 
signifi cant proteinuria. We report the case of a 48-year-old female with weight loss, cavity effusions (ascites and pleural 
effusion), and lower extremity edema. The diagnosis of lupus was established based on the presence of lymphopenia, pro-
teinuria, ANA, and positive autoantibodies (anti-Sm, anti-DNA, and anti-Ro). Because hypoalbuminemia persisted even 
with corticosteroid therapy at the dose of 1 mg/kg, protein-losing enteropathy was diagnosed by use of Tc-99m albumin 
scintigraphy. After adding azathioprine to the treatment, the symptoms subsided and serum albumin levels improved. 
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INTRODUCTION
Systemic lupus erythematosus (SLE) is an autoimmune dise-
ase that affects several systems, including the gastrointestinal 
tract.1,2 The gastrointestinal manifestations most commonly 
reported are as follows: gastroesophageal refl ux; dysphagia; 
abdominal pain; constipation; diarrhea; intestinal pseudo-
-obstruction; perforation; and hemorrhage.1 
Protein-losing enteropathy is a rare gastrointestinal condi-
tion that has been related to SLE and should be investigated 
in the presence of persistent hypoalbuminemia and lack of the 
following: signifi cant proteinuria; liver disease; malabsorption 
syndrome; and defi cient protein intake.1−3 That enteropathy 
can manifest clinically with edema or cavity effusions, depen-
ding on serum levels of albumin. In addition, the following 
symptoms can be present: nausea; vomiting; abdominal pain; 
diarrhea; and anorexia.2 We report the case of a female patient 
with SLE and protein-losing enteropathy. The diagnostic ap-
proach and treatment used are also discussed. 
CASE REPORT
The patient is a 48-year-old female of mixed heritage, who 
worked as housemaid. She reported that edema of her lower 
limbs and deterioration of her general state of health began in 
December 2009. She sought medical care in July 2010, when 
bilateral pleural effusion was evidenced, and thoracocentesis 
and pleural biopsy (discrete chronic and unspecifi c pleuritis) 
were performed. In September 2010, she was admitted to a 
regional hospital complaining of pain and increased abdominal 
volume, being then referred to our service in October 2010.
On admission, she complained of diffuse abdominal pain, 
increased abdominal volume, dyspnea on mild exertion, and 
asthenia. She reported signifi cant weight loss (approximately 
25 kg in 10 months). The physical examination showed an 
emaciated, tachycardic, tachypneic patient, with reduced re-
spiratory sounds in both pulmonary bases, diffuse abdominal 
pain on palpation, shifting dullness and positive fl uid wave 
test, and edema of lower limbs. 
Protein-losing enteropathy in systemic lupus erythematosus: case report
957Rev Bras Reumatol 2012;52(6):956-964
Table 1
Major results of the laboratory tests with respective reference values
Variable Result Reference
Hemogram
Hemoglobin (g/dL)
Hematocrit (%)
Mean corpuscular volume (fL)
Mean corpuscular hemoglobin (pg)
9.43
27.8
86.8
29.4
12–17
36–50
80–100
28–32
Leukocytes (/µL)
Neutrophils
Lymphocytes
6,360
5,316 (83%)
625 (9%)
4,000–11,000
45%–70%
20%–45%
Platelets (/µL) 80,400 150,000–450,000
Prothrombin time (s) 13.2 12.7–15.4
Partial thromboplastin time (s) 33.7 26.3–39.4
Urea (mg/dL) 42 10–50
Creatinine (mg/dL) 0.7 0.6–1.2
Erythrocyte sedimentation rate (mm/h) 4 ≤ 20
C-reactive protein (mg/dL) 4.3 ≤ 6
Protein electrophoresis
Albumin (g/dL)
Gamma globulin (g/dL)
Aspartate transaminase (U/L)
Alanine transaminase (U/L)
1.61
1.89 (polyclonal)
24
17
4.30–5.10
0.60–1.10
7–41
12–38
Urinalysis
pH
Density
Proteins
Hemoglobin
Red blood cells (cells/fi eld)
Leukocytes (cells/fi eld)
Urinary casts
6.0
1.020
+
+
10
6
Absent
4.5–8.0
1.010–1.025
Absent
Absent
0–3
0–5
Absent
24-hour proteinuria (mg/24h) 264 30–300
Ascitic fl uid
Cells (cells/µL) 
Neutrophils 
Lymphocytes 
Monocytes 
Mesothelial cells
Serum-ascites albumin gradient (SAAG)
Acid-fast bacillus
Culture
Adenosine deaminase (ADA, U/L)
Oncotic cytology
95
59%
27%
8%
6%
0.8
Negative
Negative
12.0
Negative
0
≥ 1.1 = portal hypertension
< 1.1 = probable peritoneal disease
Negative
Negative
≤ 40
Negative
ANA
1:1,280
Homogeneous nuclear
No reaction
Anti-Sm Reaction No reaction
Anti-dsDNA 1:320 No reaction
Anti-Ro Reaction No reaction
Anti-La No reaction No reaction
Complement
C3 (mg/dL)
C4 (mg/dL)
CH-50 (u/CAE)
23.8
8.5
41
90–170
12–36
≥ 60
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Diagnostic investigation was initiated, and the major 
diagnostic hypothesis was neoplasm of unknown origin. The 
laboratory tests are shown in Table 1. Upper digestive endos-
copy and colonoscopy ruled out neoplasm of the upper and low 
digestive tract. The chest, abdomen, and pelvis tomographies 
showed large volume ascites, bilateral pleural effusion, and 
pericardial effusion. 
The diagnosis of systemic lupus erythematosus was estab-
lished based on abnormal antinuclear antibody (ANA) titers, 
presence of specifi c autoantibodies (anti-Sm and anti-DNA), 
serositis, and lymphopenia. Prednisone, at the dose of 1 mg/kg, 
was initiated. Initially, the lower limb edema and ascites 
worsened, requiring repeated relief paracentesis. Due to sig-
nifi cant and persistent hypoalbuminemia, with no signifi cant 
proteinuria, normal liver function tests, and adequate protein 
intake, protein-losing enteropathy was investigated by use of 
Tc-99m albumin scintigraphy. Protein leakage was confi rmed 
in the right lower abdominal quadrant four hours after begin-
ning the study and in the subsequent images (6, 8, and 24 
hours) (Figure 1).
Azathioprine at the dose of 100 mg/day was added for four 
weeks, and the cavity effusions and lower limb edema subsided, 
and her serum albumin levels normalized. 
DISCUSSION
Protein-losing enteropathy is a condition characterized by 
excessive protein loss via the gastrointestinal tract, resulting 
in hypoproteinemia, edema, and, sometimes, cavity effu-
sions.4 It has been related to erosive gastrointestinal disorders 
(infl ammatory bowel disease, pseudomembranous colitis, 
sarcoidosis, intestinal lymphoma, erosive gastropathy), non-
erosive gastrointestinal disorders (celiac disease, microscopic 
colitis, rheumatic disorders, tropical sprue, Whipple’s disease, 
hypertrophic gastropathy), and disorders involving increased 
interstitial pressure (intestinal lymphangiectasia, congestive 
heart failure, portal hypertension, intestinal lymphatic fi stula, 
retroperitoneal fi brosis, and mesenteric tuberculosis).4,5
Protein-losing enteropathy should be considered in the 
presence of hypoalbuminemia whose most common causes 
have been ruled out, such as massive proteinuria, malnutrition, 
and decreased protein synthesis due to liver disease. The clini-
cal manifestations vary, being determined by the underlying 
disease.5 Diarrhea and other gastrointestinal symptoms might 
not be present.4 From the laboratory viewpoint, in addition to 
hypoalbuminemia, the following can be found: hypercholes-
terolemia due to the hepatic response to hypoalbuminemia; 
Figure 1
Tc-99m albumin scintigraphy showing leakage of the radiotracer in the right lower abdominal 
quadrant (4-hour static images), which increased in subsequent images.
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hypogammaglobulinemia (IgA, IgG, and IgM); and decreased 
transferrin, ceruloplasmin, and fi brinogen, because the intesti-
nal loss depends on neither protein load nor protein molecular 
weight, similarly to that of nephrotic syndrome.2,4,5
Some reviews have already described protein-losing enter-
opathy as a condition secondary to lupus.1–3 One review carried 
out in Asia has shown predominance of female patients aged 
around 30 years, the disorder being, in most cases, the initial 
manifestation of lupus.2 The Asian study by Mok et al.6 has 
reported a 3.2% prevalence of protein-losing enteropathy in 
patients with lupus. Similar data have been reported by Zheng 
et al.7 and Kim et al.8
In our patient, the criteria for diagnosing systemic 
lupus erythematosus9 were as follows: serositis (pleural 
and pericardial effusion); hematological changes (lym-
phopenia); immunological changes (positive anti-dsDNA 
and anti-Sm); and abnormal ANA titers. However, there 
is no characteristic autoantibody to identify protein-losing 
enteropathy in patients with lupus. Those laboratory 
findings are related to lupus, and not necessarily to the 
protein-losing enteropathy.6 
A mechanism that might justify protein-losing enteropathy 
in connective tissue diseases is the increased permeability 
of the intestinal microvasculature.2 Some cytokines, such as 
INF-γ, IL-6, and TNF-α,  have been implicated in that process, 
but controlled studies on the relation of those cytokines and 
disease activity and therapeutic response still lack.7,10 Other 
mechanisms reported are immune complex-mediated vasculi-
tis, lymphatic dilation, and mucosal injury, which are diffi cult 
to demonstrate microscopically.2,6
Two methods are used for diagnosing protein-losing 
enteropathy: 24-hour fecal clearance of alpha-1-antitripsin; 
and Tc-99m albumin scintigraphy. The former is non-invasive 
and can monitor the treatment response of the underlying 
disease.4,5,11 Its normal value is 2.6 mg/g of stools, refl ecting 
an intestinal clearance < 13 mL/day. Diarrhea and gastroin-
testinal bleeding can result in falsely elevated values. Alpha-
1-antitripsin is degraded at a gastric pH < 3.5, interfering 
with the result. The fecal clearance of alpha-1-antitripsin 
does not defi ne whether the site of protein leakage is gastric 
or intestinal.5
We used the Tc-99m albumin scintigraphy, which enables 
locating the site(s) of protein leakage.2 It is less expensive than 
other radiotracers (111In-chloride or 111In-transferrin), has in vivo 
stability, high sensitivity, and rare side effects (nausea, vomit-
ing, dyspnea, tachycardia, confusion, and abdominal pain). 
False-positive results occur in the presence of gastrointestinal 
bleeding. Serial images should be obtained up to 24 hours, 
increasing protein loss detection rate, possibly because of the 
intermittent nature of the process.12
The association of protein-losing enteropathy with lupus 
requires identifying the clinical and laboratory characteristics of 
the disease and ruling out other conditions by use of echocardiog-
raphy, abdominal tomography, endoscopy, and colon biopsy.13
There is no controlled study for the treatment of protein-
losing enteropathy in lupus. Reports have suggested that 
therapy should be initiated with corticosteroid alone. In case 
of no response, the association of immunosuppressants (cy-
clophosphamide, azathioprine or cyclosporine) provides rapid 
and long-lasting results. Relapses have been more frequently 
reported when corticosteroids were used in isolation, and those 
relapses have responded well to an increase in corticosteroid 
doses.2,6,7,13
Protein-losing enteropathy should be considered 
whenever patients with lupus have unexplained hypoal-
buminemia. Those patients respond well to treatment with 
corticosteroids and immunosuppressants, and, in most cases, 
the prognosis is good. 
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